{
  "protocolSection": {
    "identificationModule": {
      "nctId": "NCT04591301",
      "orgStudyIdInfo": {
        "id": "HEC113995PA•H2O-P-01/CRC-C1910"
      },
      "organization": {
        "fullName": "Sunshine Lake Pharma Co., Ltd.",
        "class": "INDUSTRY"
      },
      "briefTitle": "The Safety, Tolerability, and Pharmacokinetics Study of HEC113995 PA•H2O Tablets in Healthy Subjects",
      "officialTitle": "A Phase I, Single-Center, Randomized, Double-Blind, Placebo-Controlled, Single-Ascending Dose Clinical Study to Assess the Safety, Tolerability and Pharmacokinetics of HEC113995 PA•H2O Tablets in Healthy Subjects"
    },
    "statusModule": {
      "statusVerifiedDate": "2020-10",
      "overallStatus": "COMPLETED",
      "expandedAccessInfo": {
        "hasExpandedAccess": false
      },
      "startDateStruct": {
        "date": "2019-07-04",
        "type": "ACTUAL"
      },
      "primaryCompletionDateStruct": {
        "date": "2019-12-06",
        "type": "ACTUAL"
      },
      "completionDateStruct": {
        "date": "2019-12-06",
        "type": "ACTUAL"
      },
      "studyFirstSubmitDate": "2020-10-15",
      "studyFirstSubmitQcDate": "2020-10-15",
      "studyFirstPostDateStruct": {
        "date": "2020-10-19",
        "type": "ACTUAL"
      },
      "lastUpdateSubmitDate": "2020-10-25",
      "lastUpdatePostDateStruct": {
        "date": "2020-10-28",
        "type": "ACTUAL"
      }
    },
    "sponsorCollaboratorsModule": {
      "responsibleParty": {
        "type": "SPONSOR"
      },
      "leadSponsor": {
        "name": "Sunshine Lake Pharma Co., Ltd.",
        "class": "INDUSTRY"
      }
    },
    "oversightModule": {
      "oversightHasDmc": false,
      "isFdaRegulatedDrug": false,
      "isFdaRegulatedDevice": false
    },
    "descriptionModule": {
      "briefSummary": "The Safety, Tolerability and Pharmacokinetics Study of HEC113995 PA•H2O Tablets in Healthy Male and Female Subjects"
    },
    "conditionsModule": {
      "conditions": [
        "Major Depressive Disorder"
      ]
    },
    "designModule": {
      "studyType": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "designInfo": {
        "allocation": "RANDOMIZED",
        "interventionModel": "PARALLEL",
        "primaryPurpose": "TREATMENT",
        "maskingInfo": {
          "masking": "QUADRUPLE",
          "whoMasked": [
            "PARTICIPANT",
            "CARE_PROVIDER",
            "INVESTIGATOR",
            "OUTCOMES_ASSESSOR"
          ]
        }
      },
      "enrollmentInfo": {
        "count": 69,
        "type": "ACTUAL"
      }
    },
    "armsInterventionsModule": {
      "armGroups": [
        {
          "label": "HEC113995 PA•H2O 2.5mg",
          "type": "EXPERIMENTAL",
          "description": "Healthy subjects are given HEC113995 PA•H2O 2.5 mg in a single dose.",
          "interventionNames": [
            "Drug: HEC113995 PA•H2O tablets"
          ]
        },
        {
          "label": "HEC113995 PA•H2O 5mg",
          "type": "ACTIVE_COMPARATOR",
          "description": "Healthy subjects are given HEC113995 PA•H2O 5 mg in a single dose.",
          "interventionNames": [
            "Drug: HEC113995 PA•H2O tablets"
          ]
        },
        {
          "label": "HEC113995 PA•H2O 10mg",
          "type": "ACTIVE_COMPARATOR",
          "description": "Healthy subjects are given HEC113995 PA•H2O 10 mg in a single dose.",
          "interventionNames": [
            "Drug: HEC113995 PA•H2O tablets"
          ]
        },
        {
          "label": "HEC113995 PA•H2O 20mg",
          "type": "ACTIVE_COMPARATOR",
          "description": "Healthy subjects are given HEC113995 PA•H2O 20 mg in a single dose.",
          "interventionNames": [
            "Drug: HEC113995 PA•H2O tablets"
          ]
        },
        {
          "label": "HEC113995 PA•H2O 40mg",
          "type": "ACTIVE_COMPARATOR",
          "description": "Healthy subjects are given HEC113995 PA•H2O 40 mg in a single dose.",
          "interventionNames": [
            "Drug: HEC113995 PA•H2O tablets"
          ]
        },
        {
          "label": "HEC113995 PA•H2O 60mg",
          "type": "ACTIVE_COMPARATOR",
          "description": "Healthy subjects are given HEC113995 PA•H2O 60 mg in a single dose.",
          "interventionNames": [
            "Drug: HEC113995 PA•H2O tablets"
          ]
        },
        {
          "label": "HEC113995 PA•H2O 80mg",
          "type": "ACTIVE_COMPARATOR",
          "description": "Healthy subjects are given HEC113995 PA•H2O 80 mg in a single dose.",
          "interventionNames": [
            "Drug: HEC113995 PA•H2O tablets"
          ]
        },
        {
          "label": "placebo",
          "type": "PLACEBO_COMPARATOR",
          "description": "Healthy subjects are given placebo in a single dose.",
          "interventionNames": [
            "Drug: Placebo tablets"
          ]
        }
      ],
      "interventions": [
        {
          "type": "DRUG",
          "name": "HEC113995 PA•H2O tablets",
          "description": "Each dose of HEC113995 PA•H2O tablets will be administered with approximately 240 mL of water in the morning after fasting for at least 10 hours overnight.",
          "armGroupLabels": [
            "HEC113995 PA•H2O 10mg",
            "HEC113995 PA•H2O 2.5mg",
            "HEC113995 PA•H2O 20mg",
            "HEC113995 PA•H2O 40mg",
            "HEC113995 PA•H2O 5mg",
            "HEC113995 PA•H2O 60mg",
            "HEC113995 PA•H2O 80mg"
          ]
        },
        {
          "type": "DRUG",
          "name": "Placebo tablets",
          "description": "Placebo tablets will be administered with approximately 240 mL of water in the morning after fasting for at least 10 hours overnight.",
          "armGroupLabels": [
            "placebo"
          ]
        }
      ]
    },
    "outcomesModule": {
      "primaryOutcomes": [
        {
          "measure": "Safety and Tolerability of HEC113995 PA•H2O by Assessment of the Number of Adverse Events (AEs) Following Administration in Single Ascending Dose",
          "description": "To investigate the safety and tolerability of HEC113995 PA•H2O by assessment of AEs (non-serious and serious) following administration in SAD",
          "timeFrame": "up to 7 days"
        }
      ],
      "secondaryOutcomes": [
        {
          "measure": "PK parameters - AUC0-∞",
          "description": "area under the concentration versus time curve (AUC) from time zero to infinity",
          "timeFrame": "up to 144 hours"
        },
        {
          "measure": "PK parameters - Cmax",
          "description": "Geometric Mean of Maximum Observed Plasma Concentration of HEC113995 PA•H2O",
          "timeFrame": "up to 144 hours"
        },
        {
          "measure": "PK parameters -tmax",
          "description": "time to peak",
          "timeFrame": "up to 144 hours"
        },
        {
          "measure": "PK parameters -t½",
          "description": "apparent terminal elimination half-life",
          "timeFrame": "up to 144 hours"
        },
        {
          "measure": "PK parameters -Vz/F",
          "description": "apparent volume of distribution",
          "timeFrame": "up to 144 hours"
        },
        {
          "measure": "PK parameters - MRT",
          "description": "the Mean Residence Time",
          "timeFrame": "up to 144 hours"
        },
        {
          "measure": "PK parameters -CL/F",
          "description": "the Apparent Clearance",
          "timeFrame": "up to 144 hours"
        }
      ]
    },
    "eligibilityModule": {
      "eligibilityCriteria": "Inclusion Criteria:\n\n* 1\\. Subjects who are willing and are able to provide a written informed consent to participate in the study.\n* 2\\. Without Plan for pregnancy or pregnant within 3 months after enrollment throughout the trial.\n* 3\\. Subjects aged between 18 and 45 (both inclusive) years old.\n* 4\\. Healthy volunteers has a body weight ≥50 kg (for male) or ≥ 45kg (for female) and body mass index ≥18 and ≤28 kg/m2 at screening.\n* 5\\. Subjects, who are healthy, as having no clinically significant abnormalities in vital signs, physical examination, clinical laboratory test results, Chest X-ray and 12-lead electrocardiogram (ECG).\n\nExclusion Criteria:\n\n* 1.Subjects with serum creatinine, ALT and AST levels ≥1.5 times of the upper limit of normal value at screening.\n* 2.Subjects with a positive serology for human immunodeficiency virus (HIV) antibodies, hepatitis B surface antigen (HBsAg), hepatitis C virus (HCV) antibodies and/or TP antibodies at screening.\n* 3\\. Subjects with history of digestive system,urinary system, liver,central nervous system, blood system, endocrine system,respiratory system,immune system,cardiovascular system,and/or malignant tumor or others medical conditions (such as history of mental illness, etc.) that are not suitable for clinical trial participation;Subjects with history of epilepsy, bipolar disorder/mania, high intraocular pressure, or acute angular-closure glaucoma.\n* 4\\. Known allergic reactions or hypersensitivity to any excipient of the drug formulation(s)# anaphylaxis physique.\n* 5\\. Use of any prescription or non-prescription medications within 14 days prior to initial dosing#Use of any medications known to inhibit or induce cytochrome P enzyme drug metabolism within 28 days prior to initial dosing.\n* 6\\. Consume foods or beverages containing caffeine, xanthine, alcohol, and grapefruit within 48 hours prior to initial dosing.\n* 7\\. Positive results from urine drug screen test.\n* 8\\. History of alcoholism or drink regularly within 3 months prior to the study(defined as Alcohol consumption of \\> 21 units/week), or positive results from alcohol breath test.\n* 9.Regular smoking of more than 10 cigarettes per day within 3 months before administration of study drug, or inability to refrain from smoking during the course of the study.\n* 10\\. Donate blood or lose blood 400 mL or more within 1 month prior to initial dosing.\n* 11\\. Subjects who plan to receive or have had organ transplants.\n* 12\\. Subjects who participated in another clinical trial within 3 months prior to initial dosing.\n* 13\\. Any other condition with in the opinion of the investigator would render the patient unsuitable for inclusion in the study.",
      "healthyVolunteers": true,
      "sex": "ALL",
      "minimumAge": "18 Years",
      "maximumAge": "45 Years",
      "stdAges": [
        "ADULT"
      ]
    },
    "contactsLocationsModule": {
      "locations": [
        {
          "facility": "Shanghai Xuhui Central Hospital",
          "city": "Shanghai",
          "country": "China",
          "geoPoint": {
            "lat": 31.22222,
            "lon": 121.45806
          }
        }
      ]
    }
  },
  "derivedSection": {
    "miscInfoModule": {
      "versionHolder": "2025-10-28"
    },
    "conditionBrowseModule": {
      "meshes": [
        {
          "id": "D003865",
          "term": "Depressive Disorder, Major"
        }
      ],
      "ancestors": [
        {
          "id": "D003866",
          "term": "Depressive Disorder"
        },
        {
          "id": "D019964",
          "term": "Mood Disorders"
        },
        {
          "id": "D001523",
          "term": "Mental Disorders"
        }
      ]
    }
  },
  "hasResults": false
}